Serina Therapeutics Inc

Serina Therapeutics insider trades reveal short‑term gains, but deep dive shows a modest market cap, pre‑clinical senolytic pipeline and need for robust R&D, reimbursement, and manufacturing strategies to turn potential into lasting value.

Serina Therapeutics insider buy signals potential upside—CSO’s 6,500‑share purchase amid falling price sparks investor optimism.

Serina Therapeutics insider trading signals a short‑term strategy – CEO buys low, sells high in a day – hinting at upcoming news that could spark a rally.